Chief of the Division of General Internal Medicine; Director of Medical Marijuana Program
Dr. Julia Arnsten
is Professor of Medicine, of Epidemiology & Population Health, and of Psychiatry & Behavioral Sciences at Albert Einstein College of Medicine, and Chief of the Unified Division of General Internal Medicine (DGIM) in the Department of Medicine at Einstein/Montefiore. Her research interests are adherence with medication-taking, impact of substance use disorders on medical comorbidities, neurocognitive functioning among persons with substance use disorders, and medical cannabis. Dr. Arnsten has been continuously funded by the NIH since 1998, has published over 150 scientific manuscripts, and has been a member of over 50 NIH review panels.
Dr. Arnsten earned her M.D. from New York University School of Medicine, an M.P.H. from the Harvard School of Public Health, and a B.A. from Wesleyan University. She completed residency in Primary Care Internal Medicine at NYU Medical Center-Bellevue Hospital, and fellowship training in General Internal Medicine at Massachusetts General Hospital. Dr. Arnsten joined Einstein/Montefiore in 1996, and in 2004 was the Founding Chief of the Einstein/Montefiore DGIM. Now a vibrant academic home to over 70 faculty members, DGIM includes over 50 clinician-educators and 14 clinician-investigators who conduct research in substance use disorders, HIV/HCV prevention and treatment, tobacco cessation, chronic pain, medical education, quality improvement, and medical cannabis. Since the Division’s founding, DGIM faculty have been Principal Investigators on over 60 grants, representing over 100 million dollars in extramural funds. In recognition of the success of the Division, Dr. Arnsten has received several local and national mentoring and leadership awards
In 2017, after medical cannabis dispensaries were fully functional in NY state, Dr. Arnsten launched a medical cannabis program at Montefiore Medical Center, located in the Bronx, NY. The program operates within a traditional primary care internal medicine practice, and welcomes all patients who receive care at Montefiore. To date, the program has evaluated over 600 patients for medical cannabis, and there are currently eight physicians certified to evaluate patients for medical cannabis. In addition, investigators in Dr. Arnsten’s group have received NIH and other funding to study the impact of medical cannabis on a range of medical outcomes, including chronic pain, use of opioid medications, neurocognitive function, and inflammation. Dr. Arnsten is widely sought after to provide expert testimony on medical cannabis, and to lecture on medical cannabis within and outside of the medical community.